Saturday, 31 October 2026European Markets

SPBK1 NORD-NORGE And SPAREBANKEN VEST Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(VIANEWS) - SPBK1 NORD-NORGE (NONG.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Financial Services sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SPBK1 NORD-NORGE (NONG.OL) kr107.10 6.56% 16.76%
SPAREBANKEN VEST (SVEG.OL) kr123.80 5.93% 18.33%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SPBK1 NORD-NORGE (NONG.OL)

6.56% Forward Dividend Yield and 16.76% Return On Equity

SpareBank 1 Nord-Norge provides banking services in Northern Norway. It operates through Retail Market and Corporate Market segments. The company offers mortgage, car, boat, vehicle, and other loan related services. It also offers vehicle, home, travel, personal, and pet insurance services. In addition, the company provides various savings and pension related services, as well as debit and credit card services. Further, it offers accounting services, real estate brokerage, and leasing/sale-leaseback financing, internet banking, and mobile services. SpareBank 1 Nord-Norge was founded in 1836 and is headquartered in Tromsø, Norway.

Earnings Per Share

As for profitability, SPBK1 NORD-NORGE has a trailing twelve months EPS of kr12.37.

PE Ratio

SPBK1 NORD-NORGE has a trailing twelve months price to earnings ratio of 8.66. Meaning, the purchaser of the share is investing kr8.66 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.76%.

Volatility

SPBK1 NORD-NORGE's last week, last month's, and last quarter's current intraday variation average was a negative 0.04%, a negative 0.08%, and a positive 0.81%.

SPBK1 NORD-NORGE's highest amplitude of average volatility was 0.29% (last week), 0.61% (last month), and 0.81% (last quarter).

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is 50.2% and 33.9%, respectively.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Mar 15, 2024, the estimated forward annual dividend rate is 7 and the estimated forward annual dividend yield is 6.56%.

Yearly Top and Bottom Value

SPBK1 NORD-NORGE's stock is valued at kr107.10 at 07:30 EST, below its 52-week high of kr110.70 and way higher than its 52-week low of kr91.90.

More news about SPBK1 NORD-NORGE.

2. SPAREBANKEN VEST (SVEG.OL)

5.93% Forward Dividend Yield and 18.33% Return On Equity

Sparebanken Vest, a financial services company, provides banking and financing services in the counties of Vestland and Rogaland, Norway. The company operates through Corporate Market, Retail Market, Bulder Bank, Treasury, and Estate Agency Activities segments. It is also involved in home mortgage activities. Sparebanken Vest was founded in 1823 and is headquartered in Bergen, Norway.

Earnings Per Share

As for profitability, SPAREBANKEN VEST has a trailing twelve months EPS of kr15.11.

PE Ratio

SPAREBANKEN VEST has a trailing twelve months price to earnings ratio of 8.19. Meaning, the purchaser of the share is investing kr8.19 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.33%.

Volume

Today's last reported volume for SPAREBANKEN VEST is 46266 which is 33.45% below its average volume of 69521.

More news about SPAREBANKEN VEST.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com